Loading...
•
Nov 30, 2024
Nurix Q4 2024 Earnings Report
Reported financial results for the fourth quarter and fiscal year ended November 30, 2024, and provided a corporate update.
Key Takeaways
Nurix Therapeutics reported Q4 revenue of $13.3 million and a net loss of $58.5 million, or ($0.75) per share. The company's cash, cash equivalents, and marketable securities totaled $609.6 million as of November 30, 2024.
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL.
Received PRIME designation from the European Medicines Agency for NX-5948 in CLL.
Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom’s Macroglobulinemia.
Announced the appointment of John Northcott as Chief Commercial Officer.
Nurix
Nurix
Nurix Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Nurix plans to commence a suite of clinical trials designed to support global registration of NX-5948 for the treatment of patients with CLL and to explore its development in inflammatory diseases.
Positive Outlook
- Plans to commence a suite of clinical trials designed to support global registration of NX-5948 for the treatment of patients with CLL.
- Exploring development of NX-5948 in inflammatory diseases.
- Initiating clinical testing of NX-5948 in autoimmune cytopenias in 2025.
- Advancing a pipeline of wholly owned and partnered programs in inflammation and immunology.
- Expecting clinical updates in patients with both CLL and non-Hodgkin’s lymphoma in 2025.
Challenges Ahead
- Uncertainties related to the timing and results of preclinical studies and clinical trials.
- Whether Nurix will be able to fund development activities and achieve development goals.
- Uncertainties related to the timing and receipt of payments from Nurix’s collaboration partners.
- The impact of global business, political and macroeconomic conditions on Nurix’s business.
- Whether Nurix will be able to protect intellectual property.